KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,000 | +2.5% | 4,226 | -5.9% | 0.00% | – |
| Q2 2023 | $40,000 | +263.6% | 4,492 | +225.7% | 0.00% | – |
| Q1 2023 | $11,000 | -62.1% | 1,379 | -68.2% | 0.00% | – |
| Q4 2022 | $29,000 | -79.7% | 4,332 | -56.0% | 0.00% | – |
| Q3 2022 | $143,000 | +14200.0% | 9,847 | +7035.5% | 0.00% | – |
| Q2 2022 | $1,000 | -95.0% | 138 | -90.0% | 0.00% | – |
| Q1 2022 | $20,000 | -69.7% | 1,376 | -72.3% | 0.00% | – |
| Q4 2021 | $66,000 | +61.0% | 4,971 | +113.8% | 0.00% | – |
| Q3 2021 | $41,000 | -41.4% | 2,325 | -19.8% | 0.00% | – |
| Q2 2021 | $70,000 | +52.2% | 2,900 | +62.2% | 0.00% | – |
| Q1 2021 | $46,000 | +253.8% | 1,788 | +166.9% | 0.00% | – |
| Q4 2020 | $13,000 | – | 670 | +3090.5% | 0.00% | – |
| Q3 2020 | $0 | – | 21 | -34.4% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 32 | -97.5% | 0.00% | – |
| Q4 2019 | $22,000 | – | 1,263 | +12530.0% | 0.00% | – |
| Q3 2018 | $0 | – | 10 | +900.0% | 0.00% | – |
| Q1 2017 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 589,270 | $8,686,000 | 5.61% |
| GREAT POINT PARTNERS LLC | 874,197 | $12,886,000 | 3.11% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 383,233 | $10,805,000 | 2.44% |
| Frazier Life Sciences Management, L.P. | 1,572,192 | $23,174,000 | 1.98% |
| TANG CAPITAL MANAGEMENT LLC | 648,269 | $9,555,000 | 1.91% |
| Deep Track Capital, LP | 1,729,757 | $25,497,000 | 1.64% |
| Vivo Capital, LLC | 1,533,559 | $22,605,000 | 1.56% |
| Monashee Investment Management LLC | 264,111 | $3,893,000 | 1.13% |
| COMMODORE CAPITAL LP | 312,553 | $4,607,000 | 1.03% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,746,300 | $25,740,000 | 0.79% |